Rafael Holdings (RFL) EBITDA Margin (2017 - 2026)
Rafael Holdings' (RFL) quarterly EBITDA Margin came in at 3837.99% in Q2 2026, down 220456.0% year-over-year from N/an in Q2 2025, and down 21.69% quarter-over-quarter from 3154.03% in Q1 2026.
Powered by 
Analysis
Rafael Holdings (RFL) EBITDA Margin (2017 - 2026) Analysis & Trends
Rafael Holdings (RFL) has reported EBITDA Margin for 10 consecutive years, with 3837.99% the latest figure, recorded in Q2 2026.
- On a quarterly basis, EBITDA Margin fell 220456.0% year-over-year to 3837.99% in Q2 2026; TTM through Apr 2026 was 3717.24%, a 95208.0% decrease from a year earlier, with the FY2025 full-year figure at 3179.83%, up 1293116.0% from the prior year.
- EBITDA Margin was 3837.99% for Q2 2026 at Rafael Holdings, down from 3154.03% in the prior quarter.
- Over five years, EBITDA Margin peaked at 1633.43% in Q2 2025 and troughed at 27726.49% in Q2 2024.
- A 5-year average of 5734.51% and a median of 4031.7% in 2026 frame the typical range for EBITDA Margin.
- Across the five-year window, EBITDA Margin slumped 2348423 bps in 2024 and jumped 2609306 bps in 2025, its largest moves.
- Over 5 years, EBITDA Margin stood at 7314.29% in 2022, then jumped by 51 bps to 3619.12% in 2023, then increased by 17 bps to 3003.12% in 2024, then tumbled by 41 bps to 4225.42% in 2025, then increased by 9 bps to 3837.99% in 2026.
- The last three EBITDA Margin figures came in at 3837.99% (Q2 2026), 3154.03% (Q1 2026), and 4225.42% (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn | 34.95% |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn | -133.21% |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn | 37.40% |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn | 30.15% |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn | 32.54% |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn | -562.07% |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn | 17.93% |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn | -23.56% |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn | -25,380.93% |
| 10 | Rafael Holdings | 117.57 Mn | 117.57 Mn | 171,000.00 | -3,837.99% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Apr 30, 2026 | -3,837.99% |
| Jan 31, 2026 | -3,154.03% |
| Oct 31, 2025 | -4,225.42% |
| Jul 31, 2025 | -3,646.57% |
| Apr 30, 2025 | -1,633.43% |
| Jan 31, 2025 | -8,622.08% |
| Oct 31, 2024 | -3,003.13% |
| Jul 31, 2024 | -2,330.30% |
| Apr 30, 2024 | -27,726.49% |
| Jan 31, 2024 | -4,622.06% |
| Oct 31, 2023 | -3,619.12% |
| Jul 31, 2023 | -3,813.24% |
| Apr 30, 2023 | -4,242.25% |
| Jan 31, 2023 | -6,057.14% |
| Oct 31, 2022 | -7,314.29% |
| Jul 31, 2022 | -7,088.41% |
| Apr 30, 2022 | -6,148.68% |
| Jan 31, 2022 | -2,136.49% |
| Oct 31, 2021 | -25,926.18% |
| Jul 31, 2021 | 451.32% |